Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services save search
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
Published: 2023-07-31 (Crawled : 11:00) - globenewswire.com
RNAZ | $0.452 -1.72% -1.75% 91K
|
Professional, Scientific, and T...
|
| O: 3986.21%
H: 1.43%
C: -7.17%
mc138 ttx-mc138 positive therapeutics results
Q BioMed Inc. Provides Update to Shareholders
Published: 2023-06-23 (Crawled : 12:00) - prnewswire.com
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 3833.33%
H: 0.0%
C: -94.07%
update
Q BioMed Inc. Provides Update to Shareholders - June 23, 2023
Published: 2023-06-23 (Crawled : 13:00) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 3833.33%
H: 0.0%
C: -94.07%
update
VectivBio Publishes Invitation to the Annual General Meeting
Published: 2022-06-09 (Crawled : 21:00) - globenewswire.com
VECT | $16.85 0.12% 130K
|
Professional, Scientific, and T...
|
| O: 425.82%
H: 0.0%
C: -0.5%
Human Microbiome Therapeutics Market size to grow by USD 732.95 million from 2022 to 2027, North America to account for 41% of market growth, Technavio
Published: 2024-03-06 (Crawled : 15:30) - prnewswire.com
PTCHF | $2.64 19.97% 870
|
n/a
|
| O: 4.12%
H: 0.97%
C: 0.97%
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -4.0%
H: 4.92%
C: 4.12%
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: 4.24%
H: 0.0%
C: -7.14%
PHGE | $0.3274 -5.51% 3.82% 130K
|
Health Technology
|
| O: 211.55%
H: 18.75%
C: -4.46%
america million therapeutics market
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
UNCY | $1.07 0.0% 180K
|
Professional, Scientific, and T...
|
| O: 187.76%
H: 15.6%
C: -12.06%
drug renazorb kidney
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
Published: 2022-12-07 (Crawled : 12:20) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 181.13%
H: 0.0%
C: 0.0%
pra023 enabling positive phase 2b
Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer CellsA Potential Multi-Billion Dollar Global Market Opportunity for Cancer Treatments
Published: 2022-04-05 (Crawled : 14:20) - biospace.com/
SBFM | $0.9263 -23.45% -28.97% 10M
|
Professional, Scientific, and T...
|
| O: 175.22%
H: 9.32%
C: -9.81%
potential cancer market designation
iSpecimen Selected by U.S. Government and Private Researchers to Supply Critical Human Biospecimens for Advanced Phase of COVID-19 Research
Published: 2021-11-22 (Crawled : 14:30) - biospace.com/
ISPC | $0.2772 -6.07% -6.46% 280K
|
Professional, Scientific, and T...
|
| O: 131.5%
H: 12.12%
C: -22.04%
covid research
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
Published: 2023-07-12 (Crawled : 12:20) - globenewswire.com
RXRX | $7.94 3.12% 3.02% 7.1M
|
Professional, Scientific, and T...
|
| O: 116.37%
H: 2.18%
C: -17.66%
drug collaboration nvidia
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: 113.71%
H: 4.39%
C: -51.01%
fda clearance ongoing pharmaceuticals
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
Published: 2022-06-12 (Crawled : 00:00) - globenewswire.com
DAWN S | $15.18 -8.77% -9.62% 4.6M
|
Professional, Scientific, and T...
|
| O: 113.63%
H: 0.0%
C: 0.0%
day101 day trial one positive
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor
Published: 2021-06-02 (Crawled : 12:00) - globenewswire.com
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.02%
H: 0.6%
C: -0.74%
BCTX | $2.2 -5.94% 23K
|
Professional, Scientific, and T...
|
| O: 107.86%
H: 36.16%
C: -6.51%
eye cancer breast cancer
Verde Bio Holdings Announces Entry Into Business Combination Agreement with SensaSure Technologies, Inc.
Published: 2023-12-15 (Crawled : 12:30) - globenewswire.com
VBHI | $0.0003 60.0% 400K
|
Professional, Scientific, and T...
|
| O: 100.0%
H: 116.67%
C: 0.0%
business agreement
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Published: 2023-09-25 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.452 -1.72% -1.75% 91K
|
Professional, Scientific, and T...
|
| O: 97.29%
H: 144.27%
C: 94.66%
mc138 ttx-mc138 pre-clinical positive therapeutics results glioblastoma
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138Further Supports TTX-MC138 Application in Brain Cancer
Published: 2023-09-25 (Crawled : 17:00) - biospace.com/
RNAZ | $0.452 -1.72% -1.75% 91K
|
Professional, Scientific, and T...
|
| O: 97.29%
H: 144.27%
C: 94.66%
mc138 ttx-mc138 pre-clinical positive cancer application therapeutics results glioblastoma
Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%
Published: 2023-05-11 (Crawled : 13:00) - globenewswire.com
SBFM | $0.9263 -23.45% -28.97% 10M
|
Professional, Scientific, and T...
|
| O: 92.45%
H: 37.25%
C: -11.76%
biopharma
IMPORTANT ALERT: Halper Sadeh LLC Investigates CFMS, DFFN, ARNC, GRNA
Published: 2023-06-23 (Crawled : 17:00) - prnewswire.com
GRNA | $0.2995 -0.03% -0.07% 0
|
Professional, Scientific, and T...
|
| O: -0.37%
H: 0.68%
C: -1.29%
SFTBF | $48.635 1.64% 1.3K
|
Communications
|
| O: -4.52%
H: 0.0%
C: -1.3%
SFTBY | $24.66 -28.79% 460K
|
Information
|
| O: -3.52%
H: 0.13%
C: -0.43%
ARNC | $29.99 0.03% 0.0% 0
|
Non-Energy Minerals
|
| O: 0.0%
H: 0.2%
C: 0.07%
APO | $112.72 -0.92% -1.53% 1.4M
|
Finance
|
| O: -0.85%
H: 0.11%
C: -1.66%
FUSN | $21.4 -0.09% -0.09% 270K
|
Health Technology
|
| O: 8.24%
H: 0.0%
C: -5.07%
DFFN 4 | $6.6 11.68% -34.32% 350K
|
Health Technology
|
| O: 0.0%
H: 2.25%
C: -0.56%
CFMS | $2.26 0.44% 0
|
Health Technology
|
| O: 90.52%
H: 0.45%
C: -1.81%
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
SBFM | $0.9263 -23.45% -28.97% 10M
|
Professional, Scientific, and T...
|
| O: 83.97%
H: 18.6%
C: -4.31%
year biopharma results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.